Kura Oncology Inc buy melinda
Start price
06.11.18
/
50%
€10.64
Target price
10.12.18
€14.34
Performance (%)
16.15%
End price
10.12.18
€12.36
Summary
This prediction ended on 10.12.18 with a price of €12.36. The BUY prediction by melinda finished with a performance of 16.15%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Kura Oncology Inc | 7.837% | 7.837% | 105.652% | -14.775% |
| iShares Core DAX® | -0.922% | -1.993% | 13.399% | 16.075% |
| iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% | 46.938% |
| iShares Nikkei 225® | 2.224% | -5.187% | 20.497% | 4.643% |
| iShares S&P 500 | -0.026% | -0.918% | 30.410% | 42.418% |
Comments by melinda for this prediction
In the thread Kura Oncology Inc diskutieren
SecteurRecherche biotechnologique et médicale Agenda 05/11 Publication de résultats
Provides biopharmaceutical services
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer.
Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias.
The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer.
Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias.
The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.
Nombre d'employés : 31 personnes.
(Vom Mitglied beendet)
Stopped prediction by melinda for Kura Oncology Inc
Kura Oncology Inc
Start price
Target price
Perf. (%)
€15.33
23.09.18
23.09.18
€16.51
06.11.18
06.11.18
-27.37%
06.11.18
06.11.18
Kura Oncology Inc
Start price
Target price
Perf. (%)
€8.45
10.08.17
10.08.17
€10.50
15.08.17
15.08.17
-25.44%
15.08.17
15.08.17